FibroGen Stock News

SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also co

After losing some value lately, a hammer chart pattern has been formed for FibroGen (FGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisi

The heavy selling pressure might have exhausted for FibroGen (FGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i

FibroGen's lead candidate whiffed twice in June. It has a significant chance of reporting more unfavorable data in Q3.

FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis fails to mee

FibroGen stock has dropped significantly after the failure of its Zephyrus I trial for IPF treatment, leading the company to halt further development in this area. FGEN's future now relies on its pipe

FibroGen (NASDAQ: FGEN ) stock is heading lower on Monday after the company's Phase 3 clinical trial failed to meet its primary endpoint. This was a trial of pamrevlumab as a treatment for patients su

FibroGen Inc. FGEN, -4.06% said Monday it is discontinuing a late-stage trial of a treatment for idiopathic pulmonary fibrosis after it failed to meet its main goal. The San Francisco-based biotech sa

FibroGen???s (FGEN) phase III study, evaluating pamrevlumab as a combination therapy in certain DMD patients, fails to meet its primary endpoint.

FibroGen Inc (NASDAQ:FGEN) stock is sliding today, after the biotech company announced disappointing results from a late-stage trial of pamrevlumab, its experimental drug to treat patients with Duchen

Shares of FibroGen Inc. FGEN, -2.50% were down 5.6% premarket on Wednesday after the company announced disappointing results from a late-stage trial of pamrevlumab in non-ambulatory patients with Duch

FibroGen Inc said on Wednesday its drug to treat a type of neuromuscular disorder failed to meet the main goal in a late-stage study, sending the company's shares down about 14% in premarket trading.

SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following inves

FibroGen, Inc. results from the phase 3 LELANTOS-1 study, using pamrevlumab for the treatment of patients with non-ambulatory Duchenne Muscular Dystrophy, are expected any day now in Q2 of 2023. Resul

FibroGen, Inc. (NASDAQ:FGEN ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Michael Tung - Vice President, Corporate Strategy & Investor Relations Enrique Conterno - Chi